Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $67.10 -1.84%
EPS Growth %: -215.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -215.1%
Financial Fact:
Total operating costs and expenses: 69.24M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $20.63 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- First Carolina Financial Services CFO to retire in January 2027
- RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
